ijms-logo

Journal Browser

Journal Browser

Renin-Angiotensin-Aldosterone System in Pathologies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 21427

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
Interests: lifestyle-related diseases including hypertension; renal disease; diabetes; cardiovascular disease; cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
Interests: renal disease; molecular biology; hypertension; redox biology; inflammation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Physiology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
Interests: renal disease; renal physiology; proximal tubular function; hypertension
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Molecular & Cell Biology, School of Natural Sciences, University of California, Merced, CA 95343, USA
Interests: metabolism; insulin resistance; redox biology; lipids; metabolomics; nutrition; metabolic syndrome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The renin–angiotensin–aldosterone system (RAAS) regulates blood pressure and body fluid, and its inappropriate activation contributes to hypertension as well as cardiovascular and renal diseases. Furthermore, accumulating evidence suggests that dysregulation of the RAAS may also play an important role in the pathogenesis of other lifestyle diseases, including metabolic and neurodegenerative disorders, various cancers, dysuria, inflammatory diseases, and many others. In this Special Issue, we will collect recent advances in the study of the specific contributions of a dysregulated RAAS in lifestyle diseases, with a focus on newly discovered molecular pathways and therapeutic targets associated with the RAAS.

Prof. Dr. Akira Nishiyama
Prof. Dr. Ryousuke Satou
Prof. Dr. Jia L Zhuo
Prof. Dr. Rudy M. Ortiz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular actions of the RAAS
  • new therapeutic target for the RAAS
  • RAAS and hypertension
  • RAAS and cardiovascular diseases
  • RAAS and renal/urological diseases
  • RAAS and metabolic disorder
  • RAAS and neurodegenerative disorder
  • RAAS and infection/inflammation
  • RAAS and cancer
  • RAAS and aging

Published Papers (8 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

4 pages, 183 KiB  
Editorial
The Renin-Angiotensin-Aldosterone System in Metabolic Diseases and Other Pathologies
by Rudy M. Ortiz, Ryousuke Satou, Jia L. Zhuo and Akira Nishiyama
Int. J. Mol. Sci. 2023, 24(8), 7413; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24087413 - 18 Apr 2023
Cited by 1 | Viewed by 795
Abstract
It has been our pleasure to have been able to develop two special issues within the International Journal of Molecular Sciences: (1) Renin-Angiotensin-Aldosterone System in Pathologies and (2) Renin-Angiotensin-Aldosterone System in Metabolism & Disease [...] Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)

Research

Jump to: Editorial, Review

14 pages, 1775 KiB  
Article
Glucose Increases Hepatic Mitochondrial Antioxidant Enzyme Activities in Insulin Resistant Rats Following Chronic Angiotensin Receptor Blockade
by Jose A. Godoy-Lugo, Max A. Thorwald, Dora A. Mendez, Ruben Rodriguez, Daisuke Nakano, Akira Nishiyama and Rudy M. Ortiz
Int. J. Mol. Sci. 2022, 23(18), 10897; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231810897 - 17 Sep 2022
Cited by 3 | Viewed by 1809
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects up to 20% of the world’s population. Overactivation of the angiotensin receptor type 1 (AT1) contributes to metabolic dysfunction and increased oxidant production, which are associated with NAFLD and impaired hepatic lipid metabolism. Nuclear factor erythroid-2-related factor [...] Read more.
Non-alcoholic fatty liver disease (NAFLD) affects up to 20% of the world’s population. Overactivation of the angiotensin receptor type 1 (AT1) contributes to metabolic dysfunction and increased oxidant production, which are associated with NAFLD and impaired hepatic lipid metabolism. Nuclear factor erythroid-2-related factor 2 (Nrf2) regulates the expression of antioxidant phase II genes by binding to the antioxidant response element (ARE); however, the mechanisms by which AT1 contributes to this pathway during the progression of NAFLD remain unresolved. To investigate hepatic Nrf2 response to a hyperglycemic challenge, we studied three groups of rats (male, 10-weeks-old): (1) untreated, lean Long Evans Tokushima Otsuka (LETO), (2) untreated, obese Otsuka Long Evans Tokushima Fatty (OLETF), and (3) OLETF + angiotensin receptor blocker (OLETF + ARB; 10 mg olmesartan/kg/d × 6 weeks). Livers were collected after overnight fasting (T0; baseline), and 1 h and 2 h post-oral glucose load. At baseline, chronic AT1 blockade increased nuclear Nrf2 content, reduced expression of glutamate-cysteine ligase catalytic (GCLC) subunit, glutathione peroxidase 1 (GPx1), and superoxide dismutase 2 (SOD2), mitochondrial catalase activity, and hepatic 4-hydroxy-2-nonenal (4-HNE) content. The expression of hepatic interleukin-1 beta (IL-1β) and collagen type IV, which are associated with liver fibrosis, were decreased with AT1 blockade. Glucose increased Nrf2 translocation in OLETF but was reduced in ARB, suggesting that glucose induces the need for antioxidant defense that is ameliorated with ARB. These results suggest that overactivation of AT1 promotes oxidant damage by suppressing Nrf2 and contributing to hepatic fibrosis associated with NAFLD development. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

13 pages, 4626 KiB  
Article
Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats
by Mai Hattori, Asadur Rahman, Satoshi Kidoguchi, Nourin Jahan, Yoshihide Fujisawa, Norihiko Morisawa, Hiroyuki Ohsaki, Hideki Kobara, Tsutomu Masaki, Akram Hossain, Akumwami Steeve and Akira Nishiyama
Int. J. Mol. Sci. 2022, 23(16), 8915; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23168915 - 10 Aug 2022
Cited by 1 | Viewed by 1636
Abstract
Background: The nonsteroidal mineralocorticoid receptor blocker esaxerenone is effective in reducing blood pressure (BP). Objective: In this study, we investigated esaxerenone-driven sodium homeostasis and its association with changes in BP in Dahl salt-sensitive (DSS) hypertensive rats. Methods: In the different experimental setups, we [...] Read more.
Background: The nonsteroidal mineralocorticoid receptor blocker esaxerenone is effective in reducing blood pressure (BP). Objective: In this study, we investigated esaxerenone-driven sodium homeostasis and its association with changes in BP in Dahl salt-sensitive (DSS) hypertensive rats. Methods: In the different experimental setups, we evaluated BP by a radiotelemetry system, and sodium homeostasis was determined by an approach of sodium intake (food intake) and excretion (urinary excretion) in DSS rats with a low-salt diet (0.3% NaCl), high-salt diet (HSD, 8% NaCl), HSD plus 0.001% esaxerenone (w/w), and HSD plus 0.05% furosemide. Results: HSD-fed DSS rats showed a dramatic increase in BP with a non-dipper pattern, while esaxerenone treatment, but not furosemide, significantly reduced BP with a dipper pattern. The cumulative sodium excretion in the active period was significantly elevated in esaxerenone- and furosemide-treated rats compared with their HSD-fed counterparts. Sodium content in the skin, skinned carcass, and total body tended to be lower in esaxerenone-treated rats than in their HSD-fed counterparts, while these values were unchanged in furosemide-treated rats. Consistently, sodium balance tended to be reduced in esaxerenone-treated rats during the active period. Histological evaluation showed that esaxerenone, but not furosemide, treatment attenuated glomerulosclerosis, tubulointerstitial fibrosis, and urinary protein excretion induced by high salt loading. Conclusions: Collectively, these findings suggest that an esaxerenone treatment-induced reduction in BP and renoprotection are associated with body sodium homeostasis in salt-loaded DSS rats. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

13 pages, 2473 KiB  
Article
Immunosuppression by Mycophenolate Mofetil Mitigates Intrarenal Angiotensinogen Augmentation in Angiotensin II-Dependent Hypertension
by Ryousuke Satou, Martha Franco, Courtney M. Dugas, Akemi Katsurada and L. Gabriel Navar
Int. J. Mol. Sci. 2022, 23(14), 7680; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23147680 - 12 Jul 2022
Cited by 4 | Viewed by 1526
Abstract
Augmentation of intrarenal angiotensinogen (AGT) leads to further formation of intrarenal angiotensin II (Ang II) and the development of hypertensive kidney injury. Recent studies demonstrated that macrophages and the enhanced production of pro-inflammatory cytokines can be crucial mediators of renal AGT augmentation in [...] Read more.
Augmentation of intrarenal angiotensinogen (AGT) leads to further formation of intrarenal angiotensin II (Ang II) and the development of hypertensive kidney injury. Recent studies demonstrated that macrophages and the enhanced production of pro-inflammatory cytokines can be crucial mediators of renal AGT augmentation in hypertension. Accordingly, this study investigated the effects of immunosuppression by mycophenolate mofetil (MMF) on intrarenal AGT augmentation. Ang II (80 ng/min) was infused with or without daily administration of MMF (50 mg/kg) to Sprague-Dawley rats for 2 weeks. Mean arterial pressure (MAP) in Ang II infused rats was slightly higher (169.7 ± 6.1 mmHg) than the Ang II + MMF group (154.7 ± 2.0 mmHg), but was not statistically different from the Ang II + MMF group. MMF treatment suppressed Ang II-induced renal macrophages and IL-6 elevation. Augmentation of urinary AGT by Ang II infusion was attenuated by MMF treatment (control: 89.3 ± 25.2, Ang II: 1194 ± 305.1, and Ang II + MMF: 389 ± 192.0 ng/day). The augmentation of urinary AGT by Ang II infusion was observed before the onset of proteinuria. Elevated intrarenal AGT mRNA and protein levels in Ang II infused rats were also normalized by the MMF treatment (AGT mRNA, Ang II: 2.5 ± 0.2 and Ang II + MMF: 1.5 ± 0.1, ratio to control). Ang II-induced proteinuria, mesangial expansion and renal tubulointerstitial fibrosis were attenuated by MMF. Furthermore, MMF treatment attenuated the augmentation of intrarenal NLRP3 mRNA, a component of inflammasome. These results indicate that stimulated cytokine production in macrophages contributes to intrarenal AGT augmentation in Ang II-dependent hypertension, which leads to the development of kidney injury. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

Review

Jump to: Editorial, Research

16 pages, 2930 KiB  
Review
Angiotensin II and AT1a Receptors in the Proximal Tubules of the Kidney: New Roles in Blood Pressure Control and Hypertension
by Ana Paula de Oliveira Leite, Xiao C. Li, Sarah M. Nwia, Rumana Hassan and Jia L. Zhuo
Int. J. Mol. Sci. 2022, 23(5), 2402; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23052402 - 22 Feb 2022
Cited by 4 | Viewed by 2824
Abstract
Contrary to public perception, hypertension remains one of the most important public health problems in the United States, affecting 46% of adults with increased risk for heart attack, stroke, and kidney diseases. The mechanisms underlying poorly controlled hypertension remain incompletely understood. Recent development [...] Read more.
Contrary to public perception, hypertension remains one of the most important public health problems in the United States, affecting 46% of adults with increased risk for heart attack, stroke, and kidney diseases. The mechanisms underlying poorly controlled hypertension remain incompletely understood. Recent development in the Cre/LoxP approach to study gain or loss of function of a particular gene has significantly helped advance our new insights into the role of proximal tubule angiotensin II (Ang II) and its AT1 (AT1a) receptors in basal blood pressure control and the development of Ang II-induced hypertension. This novel approach has provided us and others with an important tool to generate novel mouse models with proximal tubule-specific loss (deletion) or gain of the function (overexpression). The objective of this invited review article is to review and discuss recent findings using novel genetically modifying proximal tubule-specific mouse models. These new studies have consistently demonstrated that deletion of AT1 (AT1a) receptors or its direct downstream target Na+/H+ exchanger 3 (NHE3) selectively in the proximal tubules of the kidney lowers basal blood pressure, increases the pressure-natriuresis response, and induces natriuretic responses, whereas overexpression of an intracellular Ang II fusion protein or AT1 (AT1a) receptors selectively in the proximal tubules increases proximal tubule Na+ reabsorption, impairs the pressure-natriuresis response, and elevates blood pressure. Furthermore, the development of Ang II-induced hypertension by systemic Ang II infusion or by proximal tubule-specific overexpression of an intracellular Ang II fusion protein was attenuated in mutant mice with proximal tubule-specific deletion of AT1 (AT1a) receptors or NHE3. Thus, these recent studies provide evidence for and new insights into the important roles of intratubular Ang II via AT1 (AT1a) receptors and NHE3 in the proximal tubules in maintaining basal blood pressure homeostasis and the development of Ang II-induced hypertension. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

11 pages, 822 KiB  
Review
Angiotensin Type-2 Receptors: Transducers of Natriuresis in the Renal Proximal Tubule
by Robert M. Carey, Helmy M. Siragy, John J. Gildea and Susanna R. Keller
Int. J. Mol. Sci. 2022, 23(4), 2317; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23042317 - 19 Feb 2022
Cited by 8 | Viewed by 2099
Abstract
Angiotensin II (Ang II) type-2 receptors (AT2R) are expressed in the adult kidney, prominently in renal proximal tubule cells (RPTCs), and play an important role in opposing renal sodium (Na+) retention induced by Ang II stimulation of Ang II [...] Read more.
Angiotensin II (Ang II) type-2 receptors (AT2R) are expressed in the adult kidney, prominently in renal proximal tubule cells (RPTCs), and play an important role in opposing renal sodium (Na+) retention induced by Ang II stimulation of Ang II type-1 receptor (AT1R). Natriuresis induced by AT1R blockade is due at least in part to AT2R activation and whole body deletion of AT2Rs reduces the natriuretic response to increased blood pressure (BP). The major endogenous AT2R agonist mediating the natriuretic response is Ang III, the Ang II heptapeptide metabolite generated by aminopeptidase A, and the principal nephron site mediating inhibition of Na+ reabsorption by the AT2R is the renal proximal tubule (RPT). AT2Rs induce natriuresis via a bradykinin, nitric oxide and cyclic GMP (cGMP) signaling cascade. Recent studies demonstrated a key role for protein phosphatase 2A (PP2A) in the AT2R-mediated natriuretic response upstream of cGMP. By inducing natriuresis, AT2Rs lower BP in the Ang II-infusion model of hypertension. PP2A activation and the natriuretic response to AT2R stimulation are defective in spontaneously hypertensive rats, a model of primary hypertension in humans. AT2R agonists are candidates for proximal tubule natriuretic agents in Na+ and fluid retention disorders. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

33 pages, 1543 KiB  
Review
Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19
by Tomas Rajtik, Peter Galis, Linda Bartosova, Ludovit Paulis, Eva Goncalvesova and Jan Klimas
Int. J. Mol. Sci. 2021, 22(23), 12800; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222312800 - 26 Nov 2021
Cited by 5 | Viewed by 2812
Abstract
Alternative branches of the classical renin–angiotensin–aldosterone system (RAS) represent an important cascade in which angiotensin 2 (AngII) undergoes cleavage via the action of the angiotensin-converting enzyme 2 (ACE2) with subsequent production of Ang(1-7) and other related metabolites eliciting its effects via Mas receptor [...] Read more.
Alternative branches of the classical renin–angiotensin–aldosterone system (RAS) represent an important cascade in which angiotensin 2 (AngII) undergoes cleavage via the action of the angiotensin-converting enzyme 2 (ACE2) with subsequent production of Ang(1-7) and other related metabolites eliciting its effects via Mas receptor activation. Generally, this branch of the RAS system is described as its non-canonical alternative arm with counterbalancing actions to the classical RAS, conveying vasodilation, anti-inflammatory, anti-remodeling and anti-proliferative effects. The implication of this branch was proposed for many different diseases, ranging from acute cardiovascular conditions, through chronic respiratory diseases to cancer, nonetheless, hypoxia is one of the most prominent common factors discussed in conjugation with the changes in the activity of alternative RAS branches. The aim of this review is to bring complex insights into the mechanisms behind the various forms of hypoxic insults on the activity of alternative RAS branches based on the different duration of stimuli and causes (acute vs. intermittent vs. chronic), localization and tissue (heart vs. vessels vs. lungs) and clinical relevance of studied phenomenon (experimental vs. clinical condition). Moreover, we provide novel insights into the future strategies utilizing the alternative RAS as a diagnostic tool as well as a promising pharmacological target in serious hypoxia-associated cardiovascular and cardiopulmonary diseases. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

16 pages, 1433 KiB  
Review
Angiotensin II and the Cardiac Parasympathetic Nervous System in Hypertension
by Julia Shanks and Rohit Ramchandra
Int. J. Mol. Sci. 2021, 22(22), 12305; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212305 - 14 Nov 2021
Cited by 15 | Viewed by 6674
Abstract
The renin–angiotensin–aldosterone system (RAAS) impacts cardiovascular homeostasis via direct actions on peripheral blood vessels and via modulation of the autonomic nervous system. To date, research has primarily focused on the actions of the RAAS on the sympathetic nervous system. Here, we review the [...] Read more.
The renin–angiotensin–aldosterone system (RAAS) impacts cardiovascular homeostasis via direct actions on peripheral blood vessels and via modulation of the autonomic nervous system. To date, research has primarily focused on the actions of the RAAS on the sympathetic nervous system. Here, we review the critical role of the RAAS on parasympathetic nerve function during normal physiology and its role in cardiovascular disease, focusing on hypertension. Angiotensin (Ang) II receptors are present throughout the parasympathetic nerves and can modulate vagal activity via actions at the level of the nerve endings as well as via the circumventricular organs and as a neuromodulator acting within brain regions. There is tonic inhibition of cardiac vagal tone by endogenous Ang II. We review the actions of Ang II via peripheral nerve endings as well as via central actions on brain regions. We review the evidence that Ang II modulates arterial baroreflex function and examine the pathways via which Ang II can modulate baroreflex control of cardiac vagal drive. Although there is evidence that Ang II can modulate parasympathetic activity and has the potential to contribute to impaired baseline levels and impaired baroreflex control during hypertension, the exact central regions where Ang II acts need further investigation. The beneficial actions of angiotensin receptor blockers in hypertension may be mediated in part via actions on the parasympathetic nervous system. We highlight important unknown questions about the interaction between the RAAS and the parasympathetic nervous system and conclude that this remains an important area where future research is needed. Full article
(This article belongs to the Special Issue Renin-Angiotensin-Aldosterone System in Pathologies)
Show Figures

Figure 1

Back to TopTop